RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS

<p>Aim. To compare effects of acetylsalicylic acid (ASA) and two clopidogrel drugs on residual platelet aggregative reactivity (RPAR). Material and methods. Patients (n=40) with ischemic heart disease aged under 70 years were involved into the crossover study. Clinical examination included que...

Full description

Bibliographic Details
Main Authors: A. A. Lomonosova, N. A. Mazur, E. A. Zolozova, E. V. Sayutina, V. V. Chigineva, N. V. Shestakova
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2015-12-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:http://www.rpcardio.ru/jour/article/view/544
id doaj-a8e211c7358a464e81e5164320845839
record_format Article
spelling doaj-a8e211c7358a464e81e51643208458392020-11-25T00:37:05ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532015-12-018216817210.1234/1819-6446-2012-2-168-172544RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORSA. A. Lomonosova0N. A. Mazur1E. A. Zolozova2E. V. Sayutina3V. V. Chigineva4N. V. Shestakova5Российская медицинская академия последипломного образованияРоссийская медицинская академия последипломного образованияРоссийская медицинская академия последипломного образованияРоссийская медицинская академия последипломного образованияРоссийская медицинская академия последипломного образованияРоссийская медицинская академия последипломного образования<p>Aim. To compare effects of acetylsalicylic acid (ASA) and two clopidogrel drugs on residual platelet aggregative reactivity (RPAR). Material and methods. Patients (n=40) with ischemic heart disease aged under 70 years were involved into the crossover study. Clinical examination included questionnaire survey , blood pressure (BP) measurement, ECG registration, 24-hour ECG and BP monitoring, determination of blood levels of total cholesterol, high density lipoproteins, triglycerides, transaminases, and creatinine, complete blood cell count, including platelets number and hemoglobin level. Besides evaluation of the platelet aggregation by optical aggregometry was performed initially , after one week ASA treatment and after every next 3 week clopidogrel treatment period.  Results. RPAR during ASA monotherapy was 56.4±0.3%. There were no significant differences in effects of original and generic clopidogrel on RPAR. Сlopidogrel therapy reduced RPAR more significantly (42.2±0.2%) than ASA monotherapy did (p=0.0003). Authors proposed definition for high level of RPAR during therapy - it is platelet aggregation more than 46%. Data analysis taking into account this criterion showed that a number of patients with high RPAR was 70 and 30% among patients treated with enterosoluble ASA and clopidogrel, respectively. Conclusion. Study results show that a significant number of patients receiving antiplatelet monotherapy does not achieve the target level of RPAR(&lt;46%). These results may be a rationale for combined therapy in patients of this type.</p>http://www.rpcardio.ru/jour/article/view/544агрегация тромбоцитовостаточная реактивностьишемическая болезнь сердцаацетилсалициловая кислотаклопидогрел
collection DOAJ
language English
format Article
sources DOAJ
author A. A. Lomonosova
N. A. Mazur
E. A. Zolozova
E. V. Sayutina
V. V. Chigineva
N. V. Shestakova
spellingShingle A. A. Lomonosova
N. A. Mazur
E. A. Zolozova
E. V. Sayutina
V. V. Chigineva
N. V. Shestakova
RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
Racionalʹnaâ Farmakoterapiâ v Kardiologii
агрегация тромбоцитов
остаточная реактивность
ишемическая болезнь сердца
ацетилсалициловая кислота
клопидогрел
author_facet A. A. Lomonosova
N. A. Mazur
E. A. Zolozova
E. V. Sayutina
V. V. Chigineva
N. V. Shestakova
author_sort A. A. Lomonosova
title RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
title_short RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
title_full RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
title_fullStr RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
title_full_unstemmed RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS
title_sort residual platelet reactivity during therapy with inhibitors of cyclooxigenase or adenosine diphosphate receptors
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2015-12-01
description <p>Aim. To compare effects of acetylsalicylic acid (ASA) and two clopidogrel drugs on residual platelet aggregative reactivity (RPAR). Material and methods. Patients (n=40) with ischemic heart disease aged under 70 years were involved into the crossover study. Clinical examination included questionnaire survey , blood pressure (BP) measurement, ECG registration, 24-hour ECG and BP monitoring, determination of blood levels of total cholesterol, high density lipoproteins, triglycerides, transaminases, and creatinine, complete blood cell count, including platelets number and hemoglobin level. Besides evaluation of the platelet aggregation by optical aggregometry was performed initially , after one week ASA treatment and after every next 3 week clopidogrel treatment period.  Results. RPAR during ASA monotherapy was 56.4±0.3%. There were no significant differences in effects of original and generic clopidogrel on RPAR. Сlopidogrel therapy reduced RPAR more significantly (42.2±0.2%) than ASA monotherapy did (p=0.0003). Authors proposed definition for high level of RPAR during therapy - it is platelet aggregation more than 46%. Data analysis taking into account this criterion showed that a number of patients with high RPAR was 70 and 30% among patients treated with enterosoluble ASA and clopidogrel, respectively. Conclusion. Study results show that a significant number of patients receiving antiplatelet monotherapy does not achieve the target level of RPAR(&lt;46%). These results may be a rationale for combined therapy in patients of this type.</p>
topic агрегация тромбоцитов
остаточная реактивность
ишемическая болезнь сердца
ацетилсалициловая кислота
клопидогрел
url http://www.rpcardio.ru/jour/article/view/544
work_keys_str_mv AT aalomonosova residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors
AT namazur residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors
AT eazolozova residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors
AT evsayutina residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors
AT vvchigineva residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors
AT nvshestakova residualplateletreactivityduringtherapywithinhibitorsofcyclooxigenaseoradenosinediphosphatereceptors
_version_ 1725302581108932608